NFKB1 and CD4+/CD56+ hematodermic neoplasm: From a therapeutic standpoint, this may validate recent efforts to suppress NFkB activation with the proteasome inhibitor bortezomib in order to inhibit cell proliferation, induce cell death, and prolong the survival of BPDCN patients23.